YAP1 and pancreatic adenocarcinoma: According to our result, high expression of YAP1 predicted poor survival outcomes in patients with LUAD, COAD, and PAAD, and was associated with more severe pathologic stages in patients with COAD, PAAD, and TGCT (Figure 3).